Poolbeg Pharma (POLB) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
09 Jan 2023 07:00 AM
RNS
Positive Initial Data Analysis in POLB 001 Trial
22 Dec 2022 10:47 AM
EQS
Poolbeg Pharma identifies new RSV drug candidates
21 Dec 2022 07:00 AM
RNS
Poolbeg identifies novel RSV drug candidates
15 Dec 2022 09:48 AM
EQS
Poolbeg Pharma makes 'interesting addition to e...
14 Dec 2022 07:00 AM
RNS
Metabolic diseases oral delivery licence signed
12 Dec 2022 02:05 PM
RNS
Second Price Monitoring Extn
12 Dec 2022 02:00 PM
RNS
Price Monitoring Extension
12 Dec 2022 11:59 AM
EQS
Poolbeg Pharma receives initial results from hu...
12 Dec 2022 07:00 AM
RNS
POLB 001 LPS human challenge trial completed
29 Nov 2022 07:00 AM
RNS
Influenza AI model build completed
21 Nov 2022 11:35 AM
EQS
Poolbeg Pharma wins first non-dilutive grant fu...
18 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
17 Nov 2022 02:05 PM
RNS
Second Price Monitoring Extn
17 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
17 Nov 2022 07:00 AM
RNS
Capital Markets Day
15 Nov 2022 10:36 AM
RNS
Poolbeg-led consortium awarded EUR 2.3m grant
09 Nov 2022 01:51 PM
EQS
Poolbeg Pharma makes virus 'breakthrough' using...
08 Nov 2022 07:00 AM
RNS
AI programme yields novel RSV drug targets
21 Oct 2022 07:00 AM
RNS
Upcoming events participation
06 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
06 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
06 Oct 2022 07:00 AM
RNS
CEO Share Purchase
04 Oct 2022 07:00 AM
RNS
POLB 001 US Patent update
21 Sep 2022 07:00 AM
RNS
Poolbeg licence of Melioidosis vaccine candidate
12 Sep 2022 07:00 AM
RNS
HC Wainwright Global Investment Conference
06 Sep 2022 02:05 PM
RNS
Second Price Monitoring Extn
06 Sep 2022 02:00 PM
RNS
Price Monitoring Extension
06 Sep 2022 07:00 AM
RNS
Interim Results
31 Aug 2022 07:25 AM
RNS
Notice of Results
29 Jul 2022 07:00 AM
RNS
Appointment of Joint Broker
20 Jul 2022 07:00 AM
RNS
POLB001 human challenge clinical trial to commence
12 Jul 2022 02:06 PM
RNS
Second Price Monitoring Extn
12 Jul 2022 02:00 PM
RNS
Price Monitoring Extension
27 Jun 2022 07:00 AM
RNS
Project update for AI model of RSV data
21 Jun 2022 04:40 PM
RNS
Second Price Monitoring Extn
21 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
26 May 2022 02:05 PM
RNS
Second Price Monitoring Extn
26 May 2022 02:00 PM
RNS
Price Monitoring Extension
26 May 2022 07:00 AM
RNS
US patents granted for POLB 001 and POLB 002
25 May 2022 04:40 PM
RNS
Second Price Monitoring Extn
25 May 2022 04:35 PM
RNS
Price Monitoring Extension
23 May 2022 01:01 PM
RNS
TR-1: Notification of major interest in shares
12 May 2022 07:00 AM
RNS
GMP manufacturing contract signed
11 May 2022 07:00 AM
RNS
Attendance at European Melioidosis Congress
27 Apr 2022 07:00 AM
RNS
Distribution in Specie update
14 Apr 2022 07:00 AM
RNS
Key POLB 002 European Patent Granted
11 Apr 2022 07:00 AM
RNS
Distribution in Specie Shareholders
04 Apr 2022 12:26 PM
RNS
Result of AGM
31 Mar 2022 07:00 AM
RNS
POLB001 Update - Clinical Trial Agreement Signed

Poolbeg Pharma is a biopharmaceutical company that develops and commercialises medicines for unmet medical needs, including rare and orphan diseases. Poolbeg Pharma focuses on developing medicines for areas of high unmet need, such as cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions like obesity. It is listed on the stock exchange under the ticker POLB.

POLB share price launched at 11p in 2021.

 

UK 100

Latest directors dealings